Key result
EARLY trial tests if very early invasive strategy reduces major cardiovascular events versus delayed strategy.
Why the study?
Optimal timing of the invasive strategy in intermediate- and high-risk NSTE-ACS patients managed without P2Y12 ADP receptor antagonist pretreatment is unknown.
Does a very early invasive strategy reduce the composite of cardiovascular death and recurrent ischemic events compared to a delayed strategy in intermediate- and high-risk NSTE-ACS patients without P2Y12 inhibitor pretreatment?
RCT (n=740)
Open-label
1:1
Yes
Does a very early invasive strategy reduce the composite of cardiovascular death and recurrent ischemic events compared to a delayed strategy in intermediate- and high-risk NSTE-ACS patients without P2Y12 inhibitor pretreatment?
The EARLY trial is designed to evaluate whether a very early invasive strategy (within 2 hours) is superior to a delayed strategy (12-72 hours) in intermediate- and high-risk NSTE-ACS patients managed without P2Y12 inhibitor pretreatment.
Answers are grounded in this paper and cite their sources.
EARLY trial will test very early versus delayed invasive strategy in NSTE-ACS without P2Y12 pretreatment; provides first randomized data on optimal timing.
According to recent literature, pretreatment with a P2Y12 ADP receptor antagonist before coronary angiography appears no longer suitable in non–ST‐segment elevation acute coronary syndrome (NSTE‐ACS) due to an unfavorable risk–benefit ratio. Optimal delay of the invasive strategy in this specific context is unknown. We hypothesize that without P2Y12 ADP receptor antagonist pretreatment, a very early invasive strategy may be beneficial. The EARLY trial (Early or Delayed Revascularization for Intermediate‐ and High‐Risk Non–ST‐Segment Elevation Acute Coronary Syndromes?) is a prospective, multicenter, randomized, controlled, open‐label, 2‐parallel‐group study that plans to enroll 740 patients. Patients are eligible if the diagnosis of intermediate‐ or high‐risk NSTE‐ACS is made and an invasive strategy intended. Patients are randomized in a 1:1 ratio. In the control group, a delayed strategy is adopted, with the coronary angiography taking place between 12 and 72 hours after randomization. In the experimental group, a very early invasive strategy is performed within 2 hours. A loading dose of a P2Y12 ADP receptor antagonist is given at the time of intervention in both groups. Recruitment began in September 2016 (n = 558 patients as of October 2017). The primary endpoint is the composite of cardiovascular death and recurrent ischemic events at 1 month. The EARLY trial aims to demonstrate the superiority of a very early invasive strategy compared with a delayed strategy in intermediate‐ and high‐risk NSTE‐ACS patients managed without P2Y12 ADP receptor antagonist pretreatment.
No takes yet. Share an insight, caveat, or question.
Lemesle et al. (2018) conducted an RCT in Intermediate- or high-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) (n=740). Very early invasive strategy (within 2 hours) vs. Delayed strategy (between 12 and 72 hours) was evaluated on Composite of cardiovascular death and recurrent ischemic events at 1 month. The EARLY trial is designed to randomize 740 patients to evaluate if a very early invasive strategy is superior to a delayed strategy for cardiovascular death and recurrent ischemic events at 1 month.
Synapse has enriched 10 related papers. Consider them for comparative context: